GLP-1 agonists, or glucagon-like peptide-1 receptor agonists, are a class of medications originally developed to manage type 2 diabetes but have gained attention for their effectiveness in promoting weight loss. These medications mimic the action of the naturally occurring hormone GLP-1, which is involved in regulating appetite and food intake. By activating GLP-1 receptors in the brain, these agonists help increase feelings of fullness, slow gastric emptying, and reduce overall appetite, leading to decreased caloric intake and subsequent weight loss.

As a collection of products, GLP-1 agonists for weight loss include several medications, each with unique formulations and dosing regimens. Some of the most well-known GLP-1 agonists include liraglutide, semaglutide, and dulaglutide. These medications are typically administered via subcutaneous injection, with varying frequencies ranging from daily to weekly, depending on the specific product. The choice of a particular GLP-1 agonist may depend on individual patient needs, preferences, and medical history.

Clinical studies have demonstrated the efficacy of GLP-1 agonists in achieving significant weight loss in individuals with obesity or overweight, often in conjunction with lifestyle modifications such as diet and exercise. These medications are generally well-tolerated, with common side effects including nausea, vomiting, and diarrhea, which tend to diminish over time. As a result, GLP-1 agonists have become an important tool in the management of obesity, offering a pharmacological option for individuals struggling to achieve weight loss through lifestyle changes alone.